Dynavax Technologies Stock Performance
| DVAX Stock | USD 13.82 0.20 1.47% |
Dynavax Technologies has a performance score of 7 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.17, which means not very significant fluctuations relative to the market. As returns on the market increase, Dynavax Technologies' returns are expected to increase less than the market. However, during the bear market, the loss of holding Dynavax Technologies is expected to be smaller as well. Dynavax Technologies right now shows a risk of 1.46%. Please confirm Dynavax Technologies semi variance, and the relationship between the treynor ratio and daily balance of power , to decide if Dynavax Technologies will be following its price patterns.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Dynavax Technologies are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, Dynavax Technologies may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
Actual Historical Performance (%)
One Day Return 1.47 | Five Day Return (0.58) | Year To Date Return 7.13 | Ten Year Return (45.68) | All Time Return (85.30) |
Last Split Factor 1:10 | Last Split Date 2014-11-10 |
1 | Dynavax Technologies Share Price Crosses Above 200-Day Moving Average - Heres What Happened - MarketBeat | 01/10/2025 |
2 | Disposition of 6666 shares by Justin Burgess of Dynavax Technologies subject to Rule 16b-3 | 02/10/2025 |
3 | Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty | 02/11/2025 |
4 | Disposition of 11209 shares by Ryan Spencer of Dynavax Technologies at 13.2 subject to Rule 16b-3 | 02/12/2025 |
5 | Disposition of 13000 shares by Robert Janssen of Dynavax Technologies subject to Rule 16b-3 | 02/13/2025 |
6 | Disposition of 22620 shares by David Novack of Dynavax Technologies subject to Rule 16b-3 | 02/18/2025 |
7 | Deep Track Capital Pushes for Board Changes at Dynavax Technologies Corp | 02/20/2025 |
8 | Dynavax Technologies Corp Announces Participation in Upcoming Investor Conferences | 02/25/2025 |
9 | We Think Dynavax Technologies Profit Is Only A Baseline For What They Can Achieve | 03/04/2025 |
10 | Dynavax to execute debt refinancing | 03/06/2025 |
11 | Disposition of 32764 shares by David Novack of Dynavax Technologies at 14. subject to Rule 16b-3 | 03/07/2025 |
12 | Wall Street Analysts See an 83.1 percent Upside in Dynavax Technologies Can the Stock Really Move This High | 03/12/2025 |
13 | AZNs Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer | 03/17/2025 |
14 | Disposition of 14020 shares by David Novack of Dynavax Technologies at 13.58 subject to Rule 16b-3 | 03/18/2025 |
15 | Why Dynavax Technologies Stock Might be a Great Pick | 03/20/2025 |
16 | Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy | 03/21/2025 |
| Begin Period Cash Flow | 150.6 M |
Dynavax |
Dynavax Technologies Relative Risk vs. Return Landscape
If you would invest 1,283 in Dynavax Technologies on December 23, 2024 and sell it today you would earn a total of 99.00 from holding Dynavax Technologies or generate 7.72% return on investment over 90 days. Dynavax Technologies is currently generating 0.1325% in daily expected returns and assumes 1.4608% risk (volatility on return distribution) over the 90 days horizon. In different words, 13% of stocks are less volatile than Dynavax, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Dynavax Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dynavax Technologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dynavax Technologies, and traders can use it to determine the average amount a Dynavax Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0907
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | DVAX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.46 actual daily | 13 87% of assets are more volatile |
Expected Return
| 0.13 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Dynavax Technologies is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dynavax Technologies by adding it to a well-diversified portfolio.
Dynavax Technologies Fundamentals Growth
Dynavax Stock prices reflect investors' perceptions of the future prospects and financial health of Dynavax Technologies, and Dynavax Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dynavax Stock performance.
| Return On Equity | 0.0448 | ||||
| Return On Asset | 6.0E-4 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 1.26 B | ||||
| Shares Outstanding | 124.07 M | ||||
| Price To Earning | 6.95 X | ||||
| Price To Book | 2.87 X | ||||
| Price To Sales | 6.18 X | ||||
| Revenue | 277.25 M | ||||
| Gross Profit | 168.99 M | ||||
| EBITDA | 45.7 M | ||||
| Net Income | 27.31 M | ||||
| Cash And Equivalents | 518.17 M | ||||
| Cash Per Share | 4.10 X | ||||
| Total Debt | 250.24 M | ||||
| Debt To Equity | 0.61 % | ||||
| Current Ratio | 2.77 X | ||||
| Book Value Per Share | 4.76 X | ||||
| Cash Flow From Operations | 66.51 M | ||||
| Earnings Per Share | 0.20 X | ||||
| Market Capitalization | 1.71 B | ||||
| Total Asset | 986.26 M | ||||
| Retained Earnings | (903.27 M) | ||||
| Working Capital | 770.31 M | ||||
| Current Asset | 199.95 M | ||||
| Current Liabilities | 28.79 M | ||||
About Dynavax Technologies Performance
Evaluating Dynavax Technologies' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Dynavax Technologies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dynavax Technologies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 445.88 | 726.55 | |
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.05 | 0.05 |
Things to note about Dynavax Technologies performance evaluation
Checking the ongoing alerts about Dynavax Technologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dynavax Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy |
- Analyzing Dynavax Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dynavax Technologies' stock is overvalued or undervalued compared to its peers.
- Examining Dynavax Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dynavax Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dynavax Technologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dynavax Technologies' stock. These opinions can provide insight into Dynavax Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.